Mayo Clinic Laboratory and Pathology Research Roundup: July 25

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Study of the Week

Study Discovers Blacks More Predisposed to Neuromyelitis Optica Spectrum Disorders and Estimates Disease Afflicts 16,000 to 17,000 Americans

nmo-960x540Neuromyelitis optica (NMO) is an autoimmune disease of water channels that predominantly damages astrocytes, specific cells in the brain. The injured astrocytes in turn cause secondary damage to myelin—the insulating sheath around nerve fibers. Hence, NMO and its spectrum disorders (NMOSD) are considered inflammatory demyelinating diseases (IDDs). Aquaporin-4–immunoglobulin G (AQP4-IgG) is the specific biomarker for NMOSD and most accurately diagnosed using a cell-based blood test. According to a multi-collaborative, population-based study on the epidemiology of NMOSD led by Mayo Clinic, an estimated 16,000 to 17,000 people in the U.S. are afflicted by the disease, especially among the black population. The study was published in the Annals of Neurology.

Published to PubMed This Week

brentwestra (@brentwestra)


Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.